215 related articles for article (PubMed ID: 33614215)
1. Dermoscopic Aspects of Cutaneous Adverse Drug Reactions.
Rossi G; da Silva Cartell A; Marchiori Bakos R
Dermatol Pract Concept; 2021 Jan; 11(1):e2021136. PubMed ID: 33614215
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Allergol Select; 2017; 1(1):96-108. PubMed ID: 30402608
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
4. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
[TBL] [Abstract][Full Text] [Related]
5. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
6. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
Barbaud A; Castagna J; Soria A
Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
[TBL] [Abstract][Full Text] [Related]
7. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
8. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
9. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
10. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
11. Severe cutaneous adverse drug reactions: a clinicoepidemiological study.
Sasidharanpillai S; Riyaz N; Khader A; Rajan U; Binitha MP; Sureshan DN
Indian J Dermatol; 2015; 60(1):102. PubMed ID: 25657416
[TBL] [Abstract][Full Text] [Related]
12. An observational study of severe cutaneous adverse reactions at a tertiary care teaching hospital.
Lekshmipriya K; Pradeesh A; Vasudevan B; Dash M; Sood A; Gera V
Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S209-S216. PubMed ID: 38144617
[TBL] [Abstract][Full Text] [Related]
13. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
14. Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis.
Chowdhury TA; Talib KA; Patricia J; Nye KD; Moosa SA
Cureus; 2021 Jun; 13(6):e15921. PubMed ID: 34336425
[TBL] [Abstract][Full Text] [Related]
15. Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients.
Na Bangxang P; Wisuthsarewong W; Nitiyarom R
Asian Pac J Allergy Immunol; 2024 Jan; ():. PubMed ID: 38183639
[TBL] [Abstract][Full Text] [Related]
16. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
AlJasser MI
Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
[TBL] [Abstract][Full Text] [Related]
17. [Drug reaction with eosinophilia and systemic symptoms].
Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
[TBL] [Abstract][Full Text] [Related]
18. Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study.
Wang F; Zhao YK; Li M; Zhu Z; Zhang X
Cutan Ocul Toxicol; 2017 Dec; 36(4):370-376. PubMed ID: 28423957
[TBL] [Abstract][Full Text] [Related]
19. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
20. The Role of Frozen Section in the Rapid Diagnosis of Severe Cutaneous Adverse Drug Reactions.
Nicholas R; Bindra MS; Mathew L; Sathishkumar D; Lakshmanan J; George R
Indian Dermatol Online J; 2021; 12(1):78-83. PubMed ID: 33768026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
